The present disclosure generally relates to therapies involving immune effector cells such as T cells engineered to express antigen receptors such as T cell receptors (TCRs) or chimeric antigen receptors (CARs). It is demonstrated herein that such antigen receptor-engineered immune effector cells may be generated in vitro/ex vivo as well as in vitro by delivering nucleic acid encoding an antigen receptor for genetic modification to cells using particles comprising the nucleic acid and a targeting molecule for targeting the immune effector cells, wherein the targeting molecule is a designed ankyrin repeat protein (DARPin). In particular, DARPins are described herein which are high-affinity binders for CDS binding to the CDS receptor on human and non-human primate (NHP) cells. Nanoparticles functionalized with CD8− targeting DARPins (CDS-DARPin) can deliver genes exclusively and specifically to human CD8.sup.+ T cells in vitro and in vivo.

A composition of an anti-psoriatic drug and methods of applying the anti-psoriatic drug for transdermal delivery of nanoparticles and entry into skin cells are provided. The composition of the anti-psoriatic drug includes a core having at least one gold nanoparticle, a shell of polyethylene glycol (PEG) strands conjugated to the core, and a plurality of alkyl groups conjugated to the shell of PEG strands. Moreover, a chain length of the plurality of alkyl groups, chain loading of the plurality of alkyl groups, or a diameter of the core is configured to optimize a distribution of the composition in the skin cells. The distribution may include skin permeability or an entry into keratinocytes. Further, methods of modulating effectiveness of the anti-psoriatic drug for inhibiting development of a psoriasis phenotype or for treatment of the psoriasis phenotype are provided.

Provided herein are methods and compositions for treating solid tumor cancers.

The present invention is directed to a nucleic acid suitable for use in treatment or prophylaxis of an infection with a coronavirus, preferably with a Coronavirus SARS-CoV-2, or a disorder related to such an infection, preferably COVID-19. The present invention is also directed to compositions, polypeptides, and vaccines. The compositions and vaccines preferably comprise at least one of said nucleic acid sequences, preferably nucleic acid sequences in association a lipid nanoparticle (LNP). The invention is also directed to first and second medical uses of the nucleic acid, the composition, the polypeptide, the combination, the vaccine, and the kit, and to methods of treating or preventing a coronavirus infection, preferably a Coronavirus infection.

Ligand-bound gold clusters and compositions comprising the ligand-bound gold clusters are used for treating liver cirrhosis and manufacturing a medicament for treatment of liver cirrhosis. Methods for treating liver cirrhosis.

The invention relates to the method for building nanoparticle-based drug carriers and the nanoparticle based drug delivery system able to manipulate the corresponding protein corona for specific and potent drug delivery to cancer cells.

Provided are octavalent influenza vaccine compositions comprising eight mRNA, each mRNA comprising an open reading frame encoding a different influenza antigen. Also provided are lipid nanoparticles (LNPs) for delivering said mRNA.

Provided are antibodies, and fragments, derivatives, and nanoparticle conjugates thereof, particularly humanized derivatives thereof, which bind to tumor antigens. Also provided are nucleic acid molecules encoding chimeric antigen receptors (CARs) that bind to tumor antigens, polypeptides and CARs encoded by the nucleic acid molecules, vectors and host cells that include the nucleic acid molecules, methods of making the same, and methods for using the same to generate a persisting population of genetically engineered T cells in a subject, expanding a population of genetically engineered T cells in a subject, modulating the amount of cytokine secreted by a T cell, reducing the amount of activation-induced calcium influx into a T cell, providing an anti-tumor immunity to a subject, treating a mammal having a MUC1-associated disease or disorder, stimulating a T cell-mediated immune response to a target cell population or tissue in a subject, and imaging a MUC1-associated tumor.

The present disclosure provides compositions which shown preferential targeting or delivery of a nucleic acid composition to a particular organ. In some embodiments, the composition comprises a steroid or sterol, an ionizable cationic lipid, a phospholipid, a PEG lipid, and a permanently cationic lipid which may be used to deliver a nucleic acid.

Methods of synthesizing gold nanodendrites (AuNDs) using amines, such as long chain amines, as a structural directing agent are disclosed. Degree of branching (DB) of the AuNDs can be tuned by adjusting certain synthetic parameters, such as solvent type, and the type and concentration of the long chain amines. DB control results in dramatic tunability of the optical properties of the AuNDs in the near infrared (NIR) range enabling improved performance, for example as a photothermal cancer therapeutic.